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ABSTRACT 
 
Li-Fraumeni syndrome was first described in 1969 as a familial syndrome that 
predisposes to the development of soft tissue sarcomas, breast cancer, leukemia, and 
other cancers. Germline alterations in the TP53 gene are, so far, the only known cause of 
the phenotype of these families. About 70% of the families that meet the classic criteria for 
Li-Fraumeni syndrome and about 20-40% of the families that meet the Chompret criteria 
have germline pathogenic variants in the TP53 gene, and for these families there are 
specific surveillance programs for early cancer detection. However, there are families that 
meet the criteria for Li-Fraumeni syndrome that do not present any alterations in the TP53 
gene, so it is important to identify other genes that may be associated with this syndrome. 
The RAD51C gene, which encodes a protein that plays different roles in several phases of 
homologous recombination, Fanconi anemia and cell cycle arrest, emerged as a possible 
candidate after the identification of a pathogenic variant in a family that meet the classic 
criteria for Li-Fraumeni. 
The aims of this work were identification of germline variants in the RAD51C gene 
in families that complied with the classic or Chompret criteria for Li-Fraumeni syndrome 
(negative for non-benign TP53 variants), identification of other candidate genes, and 
evaluation of the possible association of these variants with the phenotype of the families.  
A total of 111 genomic DNA samples from patients whose families met the criteria 
for TP53 mutation testing for molecular diagnosis of LFS were evaluated. Gastric cancer 
was included in the tumor spectrum of this syndrome due to the high incidence of this 
cancer in Portugal. Screening for RAD51C germline variants was performed by next 
generation sequencing (NGS) in 61 samples and by Sanger sequencing in 50. 
Of the 111 families analyzed, three presented a heterozygous germline pathogenic 
variant in the RAD51C gene: one family with the c.709C>T, p.(Arg237Ter), variant, and 
two families with the c.890_899del, p.(Leu297HisfsTer2), variant. The prevalence of 
germline pathogenic variants in this gene in our series was 2.7%. RAD51C pathogenic 
variants were identified in four patients with soft tissue sarcoma in the three families. 
Interestingly, two of the families were only included in this study due to the addition of 
gastric cancer as a tumor of the Li-Fraumeni spectrum, as we had also previously seen for 
germline TP53 mutations. These data corroborate the importance of including this type of 
cancer in the spectrum of this syndrome, mostly in countries with high incidence of gastric 
cancer, as is the case of Portugal. Pathogenic germline variants in the RAD51C gene 
confer an increased risk for the development of ovarian cancer, but the risk for other 
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neoplasms is not yet well established. Further studies will be needed to better define the 
risk for other cancers and thus allow referring these patients to specific surveillance 
programs and, possibly, to new therapeutic options. 
Additionally, four of 61 samples (59 without RAD51C variants) analyzed by NGS 
presented potentially deleterious variants in other genes, namely, FANCA, CHEK2, 
BUB1B and FANCM. Additional studies will be required to determine the clinical relevance 
of these variants. 
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RESUMO 
 
A síndrome de Li-Fraumeni foi inicialmente descrita em 1969 como uma síndrome 
familiar que predispõe para o desenvolvimento de sarcomas das partes moles, cancro da 
mama, leucemia e outros tipos de cancro. Alterações germinativas no gene TP53 são, até 
agora, a única causa conhecida do fenótipo apresentado por estas famílias. Cerca de 
70% das famílias que cumprem os critérios clássicos de Li-Fraumeni e cerca de 20-40% 
das famílias que cumprem os critérios de Chompret apresentam variantes germinativas 
no gene TP53, havendo programas específicos de vigilância e diagnóstico precoce para 
estas famílias. No entanto, existem famílias que cumprem os critérios clínicos para a 
síndrome de Li-Fraumeni que não apresentam qualquer alteração no gene TP53, sendo 
assim importante a identificação de outros genes que poderão estar associados com esta 
síndrome. O gene RAD51C, que codifica uma proteína com papéis importantes nas 
diversas fases da recombinação homóloga, na Anemia de Fanconi e na regulação do 
ciclo celular, surgiu como um possível candidato após a identificação de uma variante 
patogénica neste gene numa família que cumpria os critérios clássicos de Li-Fraumeni. 
Os objetivos deste trabalho foram a identificação de variantes germinativas no 
gene RAD51C em famílias que cumprem os critérios clínicos para Li-Fraumeni (sem 
variantes germinativas no gene TP53), a identificação de variantes germinativas noutros 
genes e a avaliação da possível associação destas variantes com o fenótipo destas 
famílias.  
Foram testadas 111 amostras de DNA genómico de indivíduos cujas famílias 
cumprem os critérios para teste do gene TP53 para diagnóstico molecular da síndrome 
de Li-Fraumeni, sendo que o cancro gástrico foi também incluído no espectro de tumores 
desta síndrome devido à elevada incidência desta neoplasia em Portugal, conforme 
mostramos anteriormente para mutações germinativas do gene TP53. A pesquisa de 
variantes germinativas no gene RAD51C foi realizada por sequenciação de nova geração 
(NGS) em 61 amostras e por sequenciação de Sanger em 50. 
Das 111 famílias analisadas, três são portadoras de variantes germinativas 
patogénicas em heterozigotia no gene RAD51C: uma família com a variante c.709C>T, 
p.(Arg237Ter), e duas famílias com a variante c.890_899del, p.(Leu297HisfsTer2). A 
prevalência de variantes patogénicas germinativas neste gene na nossa série foi de 
2,7%. Foram identificadas variantes patogénicas em quatro pacientes com sarcomas das 
partes moles nas três famílias. Duas destas três famílias só foram inseridas neste estudo 
devido à inclusão do cancro gástrico como um tumor do espectro de Li-Fraumeni. Este 
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resultado corrobora a importância de incluir esta neoplasia no espectro desta síndrome 
em países com alta incidência de cancro gástrico, como é o caso de Portugal. Variantes 
germinativas patogénicas no gene RAD51C conferem risco aumentado para o 
desenvolvimento de cancro do ovário, mas o risco para outras neoplasias não está ainda 
bem estabelecido. Serão necessários mais estudos para melhor definir o risco para 
outros cancros e assim poder encaminhar os portadores destas alterações para 
programas específicos de vigilância e, possivelmente, para novas opções terapêuticas. 
Adicionalmente, quatro das 61 amostras (59 sem variantes no gene RAD51C) 
analisadas por NGS apresentaram variantes provavelmente deletérias nos genes 
FANCA, CHEK2, BUB1B e FANCM. Serão necessários estudos adicionais para 
determinar a relevância clínica destas variantes.  
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I. INTRODUCTION 
 
Since Knudson’s hypothesis was proposed in retinoblastoma in 1971 (Knudson, 
1971), many other germline mutations have been associated with cancer susceptibility. 
Knudson proposed that a mutation in both alleles (the “two-hit hypothesis”) in a tumor 
suppressor gene, as is the case of the RB1 gene in retinoblastoma, is required to induce 
the carcinogenesis process. According to this theory, an individual with an heterozygotic 
germline mutation (de novo or inherited from one of the parents) in a tumor suppressor 
gene, has a high probability to acquire a second hit in the other allele either by mutation or 
epigenetic event, which will lead to its inactivation and consequently to the development of 
cancer (Balmain et al., 2003). Although less than 10% of all cancers are attributed to 
deleterious germline variants, this knowledge contributed to the development of different 
programs of screening and surveillance and to specific treatments in patients with cancer 
susceptibility (Balmain et al., 2003). 
 
 I.1 Li-Fraumeni syndrome 
 
A familial syndrome characterized by the occurrence of soft-tissue sarcomas, 
breast cancer, leukemia, and other cancers was first proposed by Drs. Frederick Li and 
Joseph Fraumeni in 1969, after retrospective evaluation of medical reports of several 
children with rhabdomyosarcoma from 17 institutions, some of them presenting families 
with high penetrance of malignancies including soft tissue sarcomas, premenopausal 
breast cancer, leukemia, and brain tumors. At that time they mentioned that this 
transmission seemed to be associated with a pleiotropic autosomal dominant gene, 
without ruling out the possibility of some environmental influence on these families like the 
possibility of a viral infection (Li and Fraumeni, 1969).  
 The classic criteria for families being classified with Li-Fraumeni Syndrome (LFS), 
comprise a proband with a sarcoma that has been diagnosed before 45 years of age, with 
a first-degree relative with any cancer before the age of 45, and another first- or second-
degree relative with either any cancer before the age of 45 or a sarcoma at any age (Li et 
al., 1988).  
 Malkin and co-workers, in 1990, revealed the presence of mutations in the tumor 
suppressor gene TP53 in the families initially reported by Li & Fraumeni (Malkin et al., 
1990). At the same time, another report revealed that an inherited TP53 mutation in a new 
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LFS family may predispose to increased susceptibility to cancer, reinforcing the role of the 
TP53 gene in carcinogenesis (Srivastava et al., 1990).  
 
I.1.1 TP53 gene and the association with LFS 
 
TP53, also known as the guardian of the genome, is a tumor suppressor gene 
located in the shorter arm of chromosome 17 (Lane, 1992). As a transcription factor, when 
activated, the protein p53 stimulates the transcription of many genes involved in several 
pathways (figure 1; Vogelstein et al., 2000; Blattner et al., 2002).  
 
Figure 1 – Cell pathways mediated by p53. The p53 activation will lead to the transcription of 
different genes (indicated in the green zone of this figure) involved in processes that prevent the 
development of tumors, for example, cell-cycle arrest, DNA repair, apoptosis, senescence, and 
modulation of autophagy.  
 
Germline mutations in TP53 are, so far, the only alteration definitively associated 
with LFS. A total of 1229 germline variants are described in the International Agency for 
Research on Cancer (IARC) TP53 database, gathered from about 347 reports up until the 
end of June of 2018 (http://p53.iarc.fr/GermlineGrowthStats.aspx). 
 Although the initial reports from Malkin et al. and Srivastava et al. identified a 
complete correlation between the families with the classic criteria for LFS and germline 
mutations in TP53 (Malkin et al., 1990; Srivastava et al., 1990), currently only about 70% 
of the families with classic LFS criteria present a germline mutation in this gene (Olivier et 
al., 2002; Varley, 2003; Mai et al., 2012). The lifetime risk of cancer in LFS is estimated to 
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be 73% for males and nearly 100% for females, the latter mainly due to the increased risk 
for breast cancer (Chompret et al. 2000). 
 
I.1.2 LFS tumor distribution  
 
 The tumor spectrum of TP53 mutation carriers is clinically heterogeneous, and 
table 1 describes the most predominant cancers. 
Table 1 – Prevalence of the most frequent tumors observed in TP53 mutation carriers. 
Core Cancer Type 
Prevalence in LFS 
(IARC TP53 
DATABASE) 
Prevalence in LFS 
(cohort studies) 
Breast cancer 29.5% 27-31% (Gonzalez et al., 2009b; Id Said et al., 2016) 
Soft tissue sarcoma 12.8% 
17.8-27% (Gonzalez et al., 2009b; Bougeard et al., 
2015; Id Said et al., 2016) 
CNS tumor 12.1% 
9-13% (Gonzalez et al., 2009b; Bougeard et al., 
2015; Id Said et al., 2016) 
Adrenocortical 
carcinoma 
10.4% 
6-13% (Gonzalez et al., 2009b; Bougeard et al., 
2015; Wasserman et al., 2015) 
Osteosarcoma 9.6% 
13-16% (Gonzalez et al., 2009b; Bougeard et al., 
2015; Id Said et al., 2016) 
Leukemia 4.3% 2-4% (Gonzalez et al., 2009b; Bougeard et al., 2015) 
LFS, Li-Fraumeni syndrome; IARC, International Agency for Research on Cancer; CNS, Central Nervous System. 
 
 According to age and gender, the tumor type distribution is variable (see figure 2). 
The childhood phase, which accounts for 22% of all cancers, is mostly characterized by 
osteosarcomas and adrenocortical carcinomas. The adrenocortical carcinoma is 
considered to be a diagnosis signature for LFS since 50-80% of children with sporadic 
adrenocortical carcinoma present a germline mutation in the TP53 gene (Libe and 
Bertherat, 2005; Wasserman et al., 2015). The most prevalent tumors of the CNS at this 
age (and between the 20-40 years of age) are choroid plexus carcinoma and 
medulloblastoma. There is a strong association between the occurrence of choroid plexus 
carcinoma and LFS, as almost 100% of children with choroid plexus carcinoma harbor an 
alteration in the TP53 gene (Krutilkova et al., 2005; Gonzalez et al., 2009b). The most 
prevalent soft tissue sarcoma is rhabdomyosarcoma, which is usually diagnosed before 
the age of five (Amadou et al., 2018). 
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 The early adulthood phase accounts for 51% of all diagnoses and this percentage 
is strongly associated with breast cancer in women. About 45-79% of female TP53 
mutation carriers develop breast cancer with the median age of 33 years (Bougeard et al., 
2015; Amadou et al., 2018). In this age interval, a series of cancers may be also 
diagnosed, including soft tissue sarcomas, osteosarcoma, leukemia, CNS tumors, 
colorectal cancer and lung cancer, all of which are diagnosed at earlier ages than 
sporadic cancers (Amadou et al., 2018). 
 In late adulthood, pancreatic and prostate cancer are the most frequently detected 
cancers. In these cases, the median age of diagnosis is slightly earlier that in sporadic 
cancers. It seems that in this phase of life the contribution of TP53 mutations to cancer 
predisposition is minimal, and that there is a mechanism that may protect cells from the 
effects of TP53 inactivation (Amadou et al., 2018).  
 
 
 
 
 
 
 
 
 
Figure 2 – Tumor spectrum in Li-Fraumeni syndrome according to age. 
               CNS, Central Nervous System.    
  
 
 Beyond this spectrum, more malignancies were described in several reports, most 
of them occurring earlier than in sporadic cases, including stomach, renal, head and neck, 
ovarian cancer, melanoma and lymphoma (Chompret et al., 2000; Varley, 2003; Gonzalez 
et al., 2009b; Amadou et al., 2018). Gastric cancer has been observed quite frequently in 
the context of LFS, especially in countries with high incidence of gastric cancer (as is the 
case of Portugal) and many authors proposed the inclusion of gastric cancer in the LFS 
tumor spectrum (Keller et al., 2004; Kim et al., 2004; Pinto et al., 2009).  
 
 
0-15 years 
Osteosarcoma 
Adrenocortical 
carcinoma 
CNS tumors 
Soft tissue sarcoma 
 
16-50 years 
Breast cancer in women 
Osteosarcoma 
Leukemia 
CNS tumors  
Colorectal cancer 
Lung cancer 
Soft tissue sarcoma 
>51 years 
Pancreatic cancer 
Prostate cancer 
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 The occurrence of several primary tumors is also observed in LFS patients. The 
risk of developing a second tumor is three to five times greater than in the general 
population (Hisada et al., 1998), and it is estimated that the cumulative risk of a second 
tumor ten years after the first cancer is around 50% in both sexes (Mai et al., 2016). 
However, it is important to note that carcinogenic effects of previous therapies can also 
cause some secondary tumors, as radiotherapy and/or chemotherapy that often cause 
hematopoietic malignancies (Felix et al., 1996; Churpek et al., 2016). 
 
I.1.3 Genetic testing for germline TP53 variants 
 
 To facilitate the identification of individuals or families with LFS and enable TP53 
gene testing and counselling, new criteria were developed by different authors (Eeles, 
1995; Birch et al., 1998). In 2009, considering the spectrum of cancers associated with 
LFS and in order to increase the families tested for TP53 mutations, the Chompret criteria 
emerged (Tinat et al., 2009). These new criteria take into account the familial 
presentation, namely when a proband has, under the age of 46 years, one of the LFS 
spectrum tumors (premenopausal breast cancer, soft tissue sarcoma, osteosarcoma, 
CNS tumor, leukemia, lung bronchoalveolar cancer or adrenocortical carcinoma) and also 
has at least a first or second degree relative with a tumor belonging to the narrow LFS 
spectrum (except breast cancer if the proband has breast cancer) before the age of 56 
years or with multiple tumors. Furthermore, it includes a proband with multiple primary 
tumors (except in the case of multiple breast cancer), two of them belonging to the LFS 
tumor spectrum and the first occurring before 46 years of age. The rare tumors are also 
covered by these criteria, if the patient has an adrenocortical carcinoma or choroid plexus 
tumor, regardless of age and family background (Tinat et al., 2009). In 2015, these criteria 
were revised and early-onset breast cancer (before the age of 31 years) was also 
included (Bougeard et al., 2015). These criteria and the classic LFS criteria are 
summarized in table 2. 
Nowadays, the revised Chompret criteria are the ones used for TP53 mutation 
testing, and it is estimated that the sensitivity of these criteria is around 82-95% and that 
20-40% of the families fulfilling these criteria present a TP53 germline mutation (Gonzalez 
et al., 2009b; Tinat et al., 2009; Mai et al., 2012; Mai et al., 2016). 
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Table 2 – Classic and Chompret criteria for LFS. 
Classic criteria 
(Li et al., 1988) 
 Proband with a sarcoma diagnosed before 45 years old 
AND a first-degree relative with any cancer before the age of 45 
AND a first- or second-degree relative with either any cancer before the age of 45  
OR a sarcoma at any age 
Revised Chompret 
criteria 
(Bougeard et al., 2015) 
 Proband with a LFS spectrum tumor* before 46 years old 
AND a first- or second-degree relative with a LFS spectrum tumor** before the age of 56  
OR with multiple tumors 
 Proband with multiple primary tumors (except multiple breast cancer), two of them 
belonging to the LFS spectrum and the first occurring before 46 years old. 
 Proband with adrenocortical carcinoma or choroid plexus tumor regardless family 
history 
 Proband with early-onset breast cancer (before the age of 31 years old) 
* including premenopausal breast cancer, soft tissue sarcoma, osteosarcoma, central nervous system tumor, leukemia, lung 
bronchoalveolar cancer or adrenocortical carcinoma 
** except breast cancer if proband have breast cancer 
LFS, Li-Fraumeni syndrome. 
  
I.1.4 Cancer surveillance in LFS 
 
 Early cancer detection greatly increases the chances of successful treatment and 
the overall survival of patients. Additionally, in hereditary syndromes, the identification of 
high-risk mutation carriers gives an even greater importance to early detection. The broad 
spectrum of tumors associated with LFS makes the implementation of a consensual 
program of screening very challenging, existing several methods approved by different 
institutes. According to National Comprehensive Cancer Network (NCCN) Guidelines, if a 
person or family meets classic or Chompret criteria a risk evaluation appointment and 
germline TP53 testing must be offered. In the case of a positive result for a pathogenic 
TP53 variant, a precise plan of exams is recommended in order to facilitate early 
detection of cancer. The exams recommended by NCCN Guidelines for individuals with 
pathogenic TP53 germline mutations are synthesized in table 3. 
Table 3 – NCCN Guidelines for screening of TP53 mutation carriers. 
Breast Cancer 
 Breast awareness from 18 years old 
 Clinical breast examination every 6-
12 months, starting at age 20y 
 20-29y: breast MRI with 
contrast  
 30-75y: breast MRI with 
contrast (may consider 
mammogram or breast 
tomosynthesis)  
 >75: Individual recommendation  
Other cancers 
 Comprehensive physical exam including 
neurologic exam every 6-12 months 
 Colonoscopy and upper endoscopy every 
2-5 years starting at 25 years of age or 5 
years before the earliest known colon 
cancer in the family 
 Annual dermatologic exam from 18 years 
of age 
 Annual whole-body MRI, examining the 
brain as part of exam or as a separate 
exam 
NCCN; National Comprehensive Cancer Network; MRI, Magnetic Resonance Imaging 
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 It is important to point out that this plan of incessant visits to the clinic also creates 
psychological, social, and emotional alterations in these patients, promoting in some 
patients states of anxiety and a reduction in the quality of life (McBride et al., 2014). 
 In addition to undergoing exams, it is important to discuss with women the option 
of resorting to prophylactic mastectomy, including its potential benefits but also the 
psychosocial effects and how it may interfere in the quality of life. For women who have 
already had a breast cancer but didn’t have a bilateral mastectomy, the continuation of the 
annual breast magnetic resonance imaging (MRI) and mammogram is important, because 
there is the possibility of a second tumor. Furthermore, in carriers at a reproductive age, it 
is important to discuss prenatal diagnosis and/or the possibility of assisted reproduction.  
 In 2016, Villani et al. observed a significantly improved survival rate in a group of 
LFS patients who carried out a rigorous program of screening, observing a five years 
overall survival of 88.8% versus 59.6% in the non-surveillance group (Villani et al., 2016).  
 
I.1.5 Other genes associated with LFS 
 
 The lack of molecular explanation for families who fulfilled the LFS clinical criteria 
but do not have a TP53 germline mutation, often called Li-Fraumeni like (LFL) families, 
triggered several studies which suggested that other genes could explain this phenotype.  
 The CHEK2 gene has in the past been associated to LFS. In 1999, Bell et al. 
identified germline heterozygous mutations in the CHEK2 gene in three unrelated families 
with criteria for LFS and without TP53 germline mutations. In 2001, Vahteristo et al. 
analyzed 44 Finish families with criteria for LFS or similar phenotypes and found a 
heterozygous mutation in the CHEK2 gene in only two families, being this mutation the 
same previously found by Bell et al. in a family with classic LFS criteria (Bell et al., 1999; 
Vahteristo et al., 2001). However, Bougeard et al. did not find any CHEK2 germline 
mutation in French LFS families (Bougeard et al., 2001). 
 More recently, other mutations in genes like POT1 and CDKN2A appear to be 
associated with the development of cancers that are part of LFS tumor spectrum in 
patients without TP53 mutations. POT1 was associated with the development of cardiac 
angiosarcomas, while some CDKN2A mutations contribute to genetic determinism of 
sarcomas (Calvete et al., 2015; Jouenne et al., 2017).  
Other genes involved in the p53 pathways have been studied in LFL families 
without TP53 mutations, namely BAX, TP63, CHEK1, BCL10, and PTEN. However, so 
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far, no association has been made between these genes and this syndrome (Stone et al., 
1999; Brown et al., 2000; Bougeard et al., 2001; Barlow et al., 2004). 
 
I.1.6 Gene-panel analysis and new candidates 
 
 The development of next-generation sequencing (NGS) techniques has greatly 
accelerated the identification of new genes associated with different syndromes. The 
possibility of analyzing a gene panel associated with cancer predisposition has allowed 
the discovery of alterations in genes that were not expected in some types of cancer.  
 In 2015, a 59-years-old patient with a soft tissue sarcoma was treated at the 
Portuguese Institute of Oncology of Porto (IPO-Porto) and, after genetic counseling, it was 
noted that her family fulfilled the classic criteria for LFS, considering her paternal uncle as 
a proband who had been diagnosed with a sarcoma at 42 years of age, his brother a first-
degree relative who had lung cancer at 35 years of age, and also two second-degree 
relatives with sarcomas, one of them being the patient in question. We screened for TP53 
germline mutations analyzing a panel of genes associated with cancer predisposition by 
NGS, and no mutations were found in the TP53 gene. Instead, a pathogenic variant was 
detected in the RAD51C gene. This incidental finding raised the hypothesis that this gene 
could explain the family phenotype and that could be a new candidate gene predisposing 
to LFS. 
 
 I.2 The RAD51C gene 
 
 Breast cancer is the most common cancer in women and accounts for 
approximately 25-30% of all cancers in LFS families (Gonzalez et al., 2009a; Id Said et 
al., 2016). The major cause of breast cancer predisposition are germline mutations in 
BRCA1 and BRCA2 genes, associated with around 5-10% of all breast cancers 
(Bonadona et al., 2005). Those genes are associated with the regulation of homologous 
recombination (HR) pathways and some other genes implicated in this pathway have 
already been described as linked to breast cancer, such as PALB2, ATM, CHEK2 and 
BRIP1 (Meijers-Heijboer et al., 2002; Renwick et al., 2006; Seal et al., 2006; Erkko et al., 
2007). Meindl et al. identified RAD51C as another cancer susceptibility gene for breast 
and ovarian cancer, although the function of RAD51C was not well understood at the date 
of the publication (Meindl et al., 2010). Nowadays, NCCN Guidelines consider the 
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RAD51C gene as a moderate-to-high risk susceptibility gene just for ovarian cancer, since 
several studies have found pathogenic variants in this gene in families with history of 
ovarian cancer (Pelttari et al., 2011; Loveday et al., 2012; Sopik et al., 2015). 
 RAD51C is a protein encoded by a 48 Mb gene composed by nine exons located 
in the long arm of chromosome 17 (17q22). The RAD51C gene has a conserved 
sequence in the Walker A and B domains that confer the ATPase activity (Figure 3) 
(French et al., 2003).  
 
 
Figure 3 – Schematic representation of the RAD51C protein. Colored in red are represented 
the N-terminal domain, in green the linker region and in silver the C-terminal domain. The Walker A 
and B domain are indicated in the figure by a black rectangle, as the nuclear localization signal. 
The ATP binding site and the BRC interacting domains are also indicated.  
 
 RAD51C was identified as part of a family of five proteins (RAD51B, RAD51C, 
RAD51D, XRCC2, and XRCC3) known as RAD51 paralogs (Masson et al., 2001). They 
share approximately 20-30% identity at the amino acid level with RAD51 and it is 
presumed that the genes encoding these factors have derived from RAD51 by gene 
duplication events and those proteins have acquired new functions (Lin et al., 2006). 
Those five paralogs form two major complexes: the BCDX2 complex (RAD51B-RAD51C-
RAD51D-XRCC2) and the CX3 complex (RAD51C-XRCC3) (Thacker, 2005). All paralogs, 
except XRCC2, have a linker region between the C-terminal and N-terminal domains that 
allow the interaction between them and the formation of those complexes (Miller et al., 
2004). The paralog C is part of both complexes and several studies show that RAD51C 
participates in the initial and in the late stages of HR (Somyajit et al., 2010). 
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 I.2.1 Homologous recombination 
 
 HR is an important cellular process in all organisms, which allows the maintenance 
of the integrity of the genome by repairing double-strand breaks (DSB) (Takata et al., 
1998). The DSB can be triggered by endogenous process or exogenous agents such as 
ionizing radiation (IR) (Ward, 1988). Some processes like meiosis or meiotic chromosome 
segregation can lead to a broken DNA replication fork usually resolved by HR (Michel et 
al., 2004). HR is a slow and mechanistically complex process that involves a large number 
of enzymes (Kowalczykowski, 2015). This process uses the sister chromatid as a repair 
template, which allows the restoring of any missing genetic information. HR occurs only in 
S and G2 phase of the cell cycle due to the availability of the sister chromatids (Orthwein 
et al., 2015). The HR pathway can be subdivided into different sub-pathways, which 
significantly differ in terms of mechanisms and enzymes required: the single strand 
annealing (SSA), the break-induced replication (BIR), the synthesis-dependent strand 
annealing (SDSA), and the canonical HR (figure 4). 
 
 
Figure 4 – Overview of homologous recombination. A schematic representation of single strand 
annealing (SSA), break-induced replication (BIR), synthesis-dependent strand annealing (SDSA), 
and canonical HR. 
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 I.2.1.1 The mechanism of HR  
 
 The first step of HR consists in the processing of the DNA ends, the degradation of 
the 5’-terminal DNA strand from the break site to generate a long 3’-ssDNA overhang. 
This process begins with the recognition of DSB by the MRN (MRE11-RAD50-NBN) 
sensor complex that recognizes and binds to the structure (Uziel et al., 2003). The 
resection is initiated by endonucleolytic cleavage of the 5’-terminated DNA in the vicinity 
of DNA end by the MRE11 that require the ATPase activity from RAD50, with NBN and 
CtIP working as cofactors (Neale et al., 2005; Garcia et al., 2011; Cannavo and Cejka, 
2014). This cleavage allows the entry sites for the long-range resection enzymes, EXO1 
or DNA2 (Bonetti et al., 2010; Cejka, 2015). While in the formation of long 3’-ssDNA 
overhang, the single strand will be coated by the RPA protein (figure 5a) (Pinto et al., 
2016). RPA protects ssDNA from the action of nucleases and blocks the formation of 
secondary structures (Wold, 1997). 
 In SSA, or RAD51-independent HR, the DNA end resection occurs until revealing 
a repetitive DNA sequence, followed by the annealing of the two resected strands 
generating a stable complex between them (Ivanov et al., 1996; Shinohara et al., 1998). 
This sub-pathway is restricted to cases in which the DSB is flanked by two repeats 
sequences and it is considered a mutagenic repair process since it causes the deletion of 
the DNA sequence between the two repeats (Ranjha et al., 2018).  
 In the remaining sub-pathways, the key recombination protein RAD51 replaces the 
RPA that was initially coating 3'-ssDNA (figure 5). The nucleoprotein filament formed by 
RAD51 and ssDNA is also called presynaptic filament (Benson et al., 1994; Sugiyama et 
al., 1997). RPA has more affinity to ssDNA than RAD51 and this replacement has to be 
moderated by a recombination moderator protein and in high eukaryotes, including 
humans, the main mediator is the BRCA2 (Yang et al., 2002; Jensen et al., 2010). The 
BRCA2 human protein has eight conserved motifs of about 35 amino acids (BRC repeats) 
that have the ability to bind directly to RAD51. Those different BRC motifs present 
distinctive functions as recruitment of RAD51 by directly binding, promotion of the ssDNA 
binding of RAD51, stabilizing the ligation between them and inhibition of the RAD51 
ligation to the dsDNA (figure 5b). Also, the initial displacement of RPA is performed by 
BRCA2 and DSS1, a direct partner of BRCA2 (Jensen et al., 2010). PALB2 also interacts 
with BRCA2 and BRCA1, localizes the BRCA2 in the DSB and promotes the formation of 
the RAD51 filament (Sy et al., 2009; Buisson et al., 2010). Additional proteins interact in 
this process facilitating and promoting the RAD51 nucleoprotein filament assembly, like 
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RAD54L, the MMS22L-TONSL complex and the RAD51 paralogs (Wolner and Peterson, 
2005; Qing et al., 2011; Piwko et al., 2016).  
When the presynaptic filament is formed (figure 5c), the next step is to look for the 
homologous sequence in the sister chromatid that will serve as template. The homology 
search mechanism is still not yet well defined, but it is proposed that indiscriminately the 
presynaptic filament will make multiple contacts with different DNA duplexes creating a 
relatively quick search in the genome (Forget and Kowalczykowski, 2012; Renkawitz et 
al., 2014). After the recognition of the sequence, the presynaptic filament invades the 
duplex DNA and, recently, the complex BRCA1-BARD1 was associated with this invasion 
by interacting directly with RAD51 (figure 5d) (Zhao et al., 2017). 
 
 
 
 
 
 
 
 
Figure 5 – Presynaptic filament formation and the invasion of template dsDNA. a) 3’-ssDNA 
coated by RPA; b) BRCA2 exchanges RPA for RAD51; c) nucleoprotein filament or presynaptic 
filament; d) invasion of template dsDNA. 
  
 The strand invasion forms a D-loop structure that will be stabilized by RPA 
preventing the formation of other additional structures and the RAD51 will be removed 
from dsDNA by RAD54 (Solinger et al., 2002). The synthesis of DNA during 
recombination is catalyzed by polymerase δ and polymerase ε (Li et al., 2009; Wilson et 
al., 2013). The process downstream to this pathway can have different outcomes 
according to the sub-pathways used: BIR, SDSA or canonical HR (figure 4).  
 In the BIR pathway, the synthesis of DNA proceeds throughout the chromosome 
arm, copying the sequence since the end of the chromosome (Llorente et al., 2008). This 
sub-pathway occurs at an elevated cost of mutagenesis and its activated only when the 
cell has no possible alternative, such as in the absence of the second DNA end. The BIR 
15 
 
pathway is important in the telomere region maintenance in the absence of telomerase 
(Sakofsky and Malkova, 2017).  
 In SDSA, the D-loop structure is disrupted and the annealing occurs between the 
two broken DNA strands, while in the canonical HR the D-loop is stabilized and proceeds 
to the arrest of the second DNA end, leading to a “double” or “complement-stabilized” D-
loop (Ranjha et al., 2018). The balance between these two pathways will be determined 
by the stability of the D-loop and by the proteins that are available and that will bind to the 
structure. BLM, RECQ1, and RETL1 are some of the proteins involved in the disruption of 
the D-loop promoting the SDSA (Bugreev et al., 2007; Barber et al., 2008; Daley et al., 
2013).  
 The regulation between SDSA and canonical HR is important because the final 
genomic result varies according to the different sub-pathways. The canonical HR is the 
only sub-pathway that can generate a crossover recombination. A crossover is the 
exchange of DNA between the two homologous loci of sister chromatids. While in terms of 
genetic evolution this process allows the increase of the species variability, in case of 
cancer this process is sometimes associated with the loss of heterozygosity (LOH) (Matos 
and West, 2014). 
 In canonical HR, following the capture of the second end, the DNA synthesis takes 
place and ligation forms an intermediated structure called double Holliday junctions (dHJs) 
(Duckett et al., 1988). Several enzymes and nucleases are involved in the resolution of 
the dHJ, like MUS81, SLX1/4 complex and the GEN1 nuclease. This resolution can lead 
to crossover or non-crossover recombination products (Ranjha et al., 2018). 
 
 I.2.1.2 RAD51C in the early and late stages of HR 
 
 Although a precise molecular mechanism of RAD51 paralogs action is not well 
established, the important role in HR is already reported by different experiments (Liu et 
al., 1998; Takata et al., 2001; French et al., 2002; Godthelp et al., 2002). Takata et al. in 
2001 was one of the first to report the role of RAD51 paralogs in HR using chicken DT40 
B-lymphocytes mutants for one of each RAD51 paralogs. They obtained cell lines 
sensitive for DNA damaging agents, like IR, mitomycin C (MMC), cisplatin and 
camptothecin. After the contact with these agents, the cell lines developed spontaneous 
chromosome aberrations, abnormal centromere numbers and had also a reduction of 
sister chromatid exchanges and defective RAD51 foci formation (Takata et al., 2001). The 
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authors compared these phenotypes with other experiments in which BRCA2 was 
mutated and reported similar phenotype alterations, suggesting a role of RAD51 paralogs 
in assisting the RAD51 assembly at sites of DSB DNA (Patel et al., 1998; Yuan et al., 
1999; Yu et al., 2000; Rodrigue et al., 2006).  
 In other reports, the BCDX2 complex (RAD51B-RAD51C-RAD51D-XRCC2) is 
shown to be able to bind single and double DNA strands and has the ability to hydrolyze 
ATP (Braybrooke et al., 2000; Sigurdsson et al., 2001). The RAD51C and RAD51B also 
form a stable complex capable of interacting with RPA and RAD51, functioning as a 
mediator in RPA exchange for RAD51 during the formation of the nucleoprotein filament 
(Sigurdsson et al., 2001; Rodrigue et al., 2006). Moreover the CX3 complex (RAD51C-
XRCC3) and the XRCC2-RAD51D are associated with the early phase of HR, exhibiting 
the capacity of homologous pairing (Kurumizaka et al., 2001; Kurumizaka et al., 2002).  
 Although none of the RAD51 paralogs has nuclease activity, the CX3 complex was 
for many years associated with the ability of binding specifically with HR double junctions 
promoting the HJ branch migration and resolution (Yokoyama et al., 2003; Liu et al., 2004; 
Yokoyama et al., 2004; Sharan and Kuznetsov, 2007). However, the identification of 
GEN1 as the major nuclease responsible for resolution of dHJs raises some questions 
about the role of RAD51C in this process. Further studies are needed to improve our 
knowledge about the RAD51C in all sub-pathways of the HR (Ip et al., 2008).  
 
I.2.2 DNA interstrand cross-link (ICL) 
 
 In the reports of Takata et al. and Liu et al., the lack of RAD51 paralogs leads to 
chromosome aberrations, defective gene targeting and genome instability in presence of 
MMC, diepoxybutane (DEB) and cisplatin (Liu et al., 1998; Takata et al., 2001). This kind 
of phenotype is usually observed in Fanconi Anemia (FA) and is caused by errors in 
resolving the DNA ICLs induced by these agents (Joenje and Patel, 2001). DNA ICLs are 
the most deleterious DNA lesions since they block the replication and the transcription of 
DNA. 
 FA is a genetic disorder that, so far, has 22 genetic subtypes identified caused by 
mutations in different genes (see table 4).  
 
 
17 
 
Table 4 – Fanconi Anemia genes. 
FA GENE ALTERNATIVE NAME ESTABLISHED MOLECULAR FUNCTION 
FANCA FANCH Belongs to the multisubunit FA complex 
FANCB FAAP95 Belongs to the multisubunit FA complex 
FANCC - Belongs to the multisubunit FA complex 
FANCD1 BRCA2 Effector Recruitment in DNA repair 
FANCD2 - 
Forms a heterodimer with FANCI 
Is monoubiquitylated by the multisubunit FA complex 
Recruits the DNA repair proteins 
FANCE - Belongs to the multisubunit FA complex 
FANCF - Belongs to the multisubunit FA complex 
FANCG XRCC9 Belongs to the multisubunit FA complex 
FANCI KIAA1794 
Forms a heterodimer with FANCD1 
Is monoubiquitylated by the multisubunit FA complex 
Recruits the DNA repair proteins 
FANCJ BRIP1, BACH1 DNA helicase essential for BRCA1 dependent DNA repair 
FANCL PHF9 Ubiquitin ligase protein that mediates monoubiquitination of 
FANCD2 and FANCI 
FANCM - 
Belongs to the multisubunit FA complex 
DNA helicase involved in repair Hollyday junctions 
FANCN PALB2 Ability to recruit BRCA2 and RAD51 to DNA breaks 
FANCO RAD51C, RAD51L2 Essential for the HR pathway of DNA repair 
FANCP SLX4 
Resolution of DNA secondary structures generated during DNA 
repair and recombination like Holliday junctions 
Interact with several nucleases, including ERCC4 
FANCQ ERCC4, XPF DNA repair endonuclease 
FANCR RAD51 Essential for the HR pathway of DNA repair 
FANCS BRCA1 Essential for the HR pathway of DNA repair 
FANCT UBE2T E2 ubiquitin ligase that in association with FANCL catalyze the 
monoubiquitination of FANCD2 and FANCI 
FANCU XRCC2 Essential for the HR pathway of DNA repair 
FANCV MAD2L2, REV7 Translesion DNA synthesis 
FANCW RFWD3 Promotes ATR activation and HR 
FA, Fanconi anemia; HR, homologous recombination  
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This disease is characterized by bone marrow failure, developmental anomalies 
and susceptibility to cancer (Lobitz and Velleuer, 2006). The diagnosis of FA is made by a 
cytogenetic analysis of chromosome breakage of lymphocytes cells from the patients in 
the presence of ICL agents, like MMC or DEB (Shimamura et al., 2002).   
In cells during the G1 phase of cell cycle, the nucleotide excision repair (NER) can 
remove the ICLs (Deans and West, 2011). However, in S and G2 phase these errors lead 
to blockage of the replication fork and the initial steps of DNA ICLs resolution are the key 
function of the FA pathway, being the monoubiquitination of FANCD2 and FANCI 
heterodimer the process that regulates the DNA damage response. After DNA damage, 
by post-translational modifications of FA proteins, the core complex is formed through the 
assembly of at least nine FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, 
FANCG, FANCT, FANCM and FANCL) and two accessory proteins (FAAP20 and 
FAAP100) (Garcia-Higuera et al., 2001; Smogorzewska et al., 2007). This core complex 
will be able to monoubiquitylate the FANCD2-FANCI heterodimer (Nalepa and Clapp, 
2018). The modified FANCD2-FANCI complex will be withheld in the chromatin and will 
make the recruitment of nucleases and polymerases that are required for the repair 
process (see figure 6) (Yamamoto et al., 2011; Lachaud et al., 2014). In this process the 
proteins from HR, namely the RAD51C, mediate the stabilization of the replication fork 
(Sobeck et al., 2006; Schwab et al., 2015; Nalepa and Clapp, 2018). 
FANCO (or RAD51C) is one of the FA genes participating in early HR and 
mutations in this gene were associated in a family with a characteristic phenotype of FA 
(Vaz et al., 2010). Other studies identified monoallelic mutations in RAD51C causing 
ovarian and breast cancer, although no hematological anomalies were observed (Meindl 
et al., 2010; Somyajit et al., 2010; Somyajit et al., 2012).  
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Figure 6 – The Fanconi Anemia pathway in response of DNA damage. In phase S and G2 after 
the DNA damage and formation of an ICL occurs the assembly of the FA core complex that will 
trigger the monoubiquitylation of FANCD2-FANCI complex. This complex will coordinate the DNA 
damage response. 
 
I.2.3 DNA damage response and cell cycle  
 
 The response to DNA damage involves a complex network that coordinates the 
DNA damage repair by recruiting the machinery to sites of damage and coordinates the 
progression of cell in the cell cycle, activating the checkpoints and inducing cell arrest or 
apoptosis.  
 The ATM and the ATR kinases are principal players in the DNA damage signaling 
mechanism, phosphorylating the subtracts required for cell cycle control and activation of 
DNA repair pathways (Shiloh, 2003; Bartek and Lukas, 2007). During the interphase, the 
recruitment of MRN complex triggers ATM phosphorylation (Petrini and Stracker, 2003). 
This activation will initiate a phospho-signaling cascade, leading to phosphorylation of the 
checkpoint effector kinase CHK2 (Matsuoka et al., 1998; Buscemi et al., 2001). In parallel, 
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the MRN complex will recruit the machinery to generate the 3'-ssDNA overhangs that will 
be coated by RPA. The RPA-coated ssDNA tails trigger the ATR-dependent signaling, 
activating the CHK1 checkpoint kinase (Zou and Elledge, 2003; Garcia-Muse and Boulton, 
2005; Adams et al., 2006). The activation of CHK1 and CHK2 will inhibit the cyclin-
dependent kinases (CDK), and consequently impede the progression of the cell cycle for 
mitosis (West, 2003).  
 Badie et al. observed the accumulation of RAD51C into sites of DNA damage 
before and independently of the assembly of RAD51 into ssDNA. They proved that 
RAD51C was involved in the activation of CHK2, promoting its phosphorylation in phase S 
and G2 (see figure 7). Although the mechanism is not totally understood, the authors 
thought that RAD51C could act as a recruitment mediator of checkpoint kinases or like a 
transduction or amplifier of CHK2 phosphorylation (Badie et al., 2009). Badie et al. 
showed that the depletion of CHK2 causes the progression of cells into phase G2/M when 
exposed to IR similar to the results of RAD51C depletion. After the induction of DSB, by 
IR, they observed an increase of cells entering mitosis, the accumulation of endogenous 
DNA damage and mitosis with unrepaired DSBs (Badie et al., 2009; Somyajit et al., 2010).  
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Figure 7 – The role of RAD51C in damage response. After an ICL or a DSB, ATM activation 
occurs that will activate the FA pathway and HR. Besides the intervention in both pathways, 
RAD51C is also implicated in the activation of CHK2 and in the regulation of checkpoints. 
Alterations on RAD51C, represented in red arrows, will lead to genome instability, Fanconi Anemia 
and cancer. 
  
 The participation of the C paralog of RAD51 in several steps of HR, in the FA 
pathway and in regulation of DNA damage response, along with the identification of a 
pathogenic variant in a LFS family, lead us to hypothesize that germline pathogenic 
variants in RAD51C (or even in other genes involved in these pathways) may be 
responsible for increased susceptibility for developing cancer in families that comply with 
the clinical LFS criteria but do not have germline pathogenic TP53 variants. 
  
  
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
II. AIMS 
 
  
II.   AIMS 
  
24 
 
 
 
25 
 
 
II. AIMS 
The general aim of this study was to search for germline variants in the RAD51C 
gene in families with clinical criteria for LFS molecular testing without TP53 germline 
variants.  
The specific aims of this study were:  
 To identify germline variants in the RAD51C gene in a series of families that 
complied with the classic criteria or the Chompret criteria for LFS molecular 
testing and that were negative for non-benign TP53 variants; 
 To identify other candidate genes involved in HR or FA pathways; 
 To discuss possible associations of gene variants with the phenotype. 
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III. MATERIALS AND METHODS 
 
III.1 Patients and sample collection 
 
A consecutive series of DNA samples was collected from 61 patients that met the 
classic or Chompret criteria for analysis by gene-panel NGS. Those patients had been 
referred to the Genetics Department of IPO-Porto between October 2014 and October 
2016 for TP53 germline variant analysis. All patients with non-benign TP53 germline 
variants were excluded from this study. In this series, only one family had the classical 
criteria for LFS, whereas the remaining 60 families studied met the Chompret criteria (the 
criteria were applied to each family as a whole and not necessarily to the proband). 
Furthermore, gastric cancer was included in the LFS tumor spectrum due to the high 
incidence of this disease in Portugal, as discussed previously by our group (Pinto et al., 
2009). 
Another series of DNA samples from 50 patients that met the classic and Chompret 
criteria were retrospectively selected for analysis by Sanger sequencing. Those patients 
had been referred to the Genetics Department of IPO-Porto between April 2000 and 
September 2014 for TP53 germline variant analysis. The criteria used for this selection 
was the same as that of the series analyzed by NGS and one family met the classic 
criteria for LFS and the remaining 49 met the Chompret criteria.  
Whenever possible, the samples from family members of the index patients were 
also studied. 
 
III.2 Gene-panel analysis by NGS 
 
A total of 61 DNA samples were analyzed by NGS using TruSight Cancer [Illumina, San 
Diego, CA, USA] that includes a panel of 94 genes associated with cancer predisposition (table 
5) for screening of germline variants. For this purpose, the Nextera DNA transposome 
[Illumina] was used to convert genomic DNA (gDNA) into adapter-tagged indexed libraries. 
Approximately 50 ng of gDNA were used in the tagmentation process, which involves 
simultaneous fragmentation and adapter tagging of gDNA followed by adapter ligation. 
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Table 5 – TruSight Cancer gene list. 
Genes  
AIP 
ALK 
APC 
ATM 
BAP1 
BLM 
BMPR1A 
BRCA1 
BRCA2 
BRIP1 
BUB1B 
CDC73 
CDH1 
CDK4 
CDKN1C 
CDKN2A 
CEBPA 
CEP57 
CHEK2 
CYLD 
DDB2 
DICER1 
DIS3L2 
EGFR 
EPCAM 
ERCC2 
ERCC3 
ERCC4 
ERCC5 
EXT1 
EXT2 
EZH2 
FANCA 
FANCB 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCG 
FANCI 
FANCL 
FANCM 
FH 
FLCN 
GATA2 
GPC3 
HNF1A 
HRAS 
KIT 
MAX 
MEN1 
MET 
MLH1 
MSH2 
MSH6 
MUTYH 
NBN 
NF1 
NF2 
NSD1 
PALB2 
PHOX2B 
PMS1 
PMS2 
PRF1 
PRKAR1A 
PTCH1 
PTEN 
RAD51C 
RAD51D 
RB1 
RECQL4 
RET 
RHBDF2 
RUNX1 
SBDS 
SDHAF2 
SDHB 
SDHC 
SDHD 
SLX4 
SMAD4 
SMARCB1 
STK11 
SUFU 
TMEM127 
TP53 
TSC1 
TSC2 
VHL 
WRN 
WT1 
XPA 
XPC 
 
The tagmented DNA was purified using Solid Phase Reversible Immobilization 
(SPRI) beads, and then it was analyzed by high-resolution capillary electrophoresis in a 
QIAxcel Advanced system [QIAGEN, Hilden, Germany]. The electrophoresis results were analyzed 
using the QIAxcel ScreenGel software [QIAGEN]. 
The purification reaction was followed by the first PCR amplification, in which the 
purified tagmented DNA was amplified and index adapters required for cluster generation 
and sequencing were added. The tagmented DNA was amplified in a solution containing 
20 μL of Nextera Library Ampification Mix [Illumina], 5 μL of Index 1 [Illumina] and 5 μL of Index 2 
[Illumina]. PCR reaction was performed in a thermocycler [Veriti™ Thermal Cycler, Applied Biosystems] 
according to the conditions of table 6. 
 
Table 6 – PCR program used in the first PCR amplification. 
Step Temp Time  
Initial Denaturation 72ºC 3 min 
Initial Denaturation 98ºC 30 sec 
Denaturation 98ºC 10 sec 
Annealing 60ºC 30 sec 
Extension 72ºC 30 sec 
Final Extension 72ºC 5 min 
Pause 10ºC ∞ 
 
10 cycles 
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The PCR products were purified using the SPRI beads and then quantified using a 
Qubit 2.0 Fluorometer [Invitrogen, Carlsbad, CA, USA]. The quality of the library was assessed using 
high-resolution capillary electrophoresis in a QIAxcel Advanced system [QIAGEN]. 
Approximately 500 ng of individual libraries were pooled in batches of 12 samples, 
followed by a first hybridization. The reaction consisted on mixing 40 μL of DNA library 
sample, 50 μL of Enrichment Hybridization Buffer [Illumina] and 10 μL of TruSight Content 
Set CSO [Illumina]. This step mixes the DNA library with capture probes to targeted regions of 
interest and it was performed according to the conditions of table 7. 
Table 7 – PCR program used in the first hybridization. 
Step Temp Time  
Initial step 95ºC 3 min 
Hybridization 94ºC (-2ºC per cycle) 30 sec 
Pause 58ºC 
For at least 90 minutes 
and up to a maximum of 
24 hours 
 
The first hybridization was followed by capture of the probes hybridized to the 
target regions of interest using streptavidin beads. The biotinylated gDNA fragments 
bound to the streptavidin beads were magnetically pulled down from the solution. The 
partly enriched gDNA fragments were then eluted from the beads and subjected to a 
second round of hybridization and second capture. 
The capture library was purified with SPRI beads, which was followed by a second 
PCR amplification. The capture library was amplified in a solution containing 5 μL of PCR 
Primer Cocktail [Illumina] and 20 μL of Nextera Enrichment Amplification Mix [Illumina]. PCR 
reaction was performed in a thermocycler [Veriti™ Thermal Cycler, Applied Biosystems] according to the 
conditions of table 8. 
 
 
 
 
 
10 cycles 
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Table 8 – PCR program used in the second PCR amplification. 
Step Temp Time  
Initial Denaturation 72ºC 3 min 
Initial Denaturation 98ºC 30 sec 
Denaturation 98ºC 10 sec 
Annealing 60ºC 30 sec 
Extension 72ºC 30 sec 
Final Extension 72ºC 5 min 
Pause 10ºC ∞ 
 
The PCR products were purified using SPRI beads. The tagged and amplified 
sample libraries were quantified using a Qubit 2.0 Fluorometer [Invitrogen] and the quality of 
the library was checked using high-resolution capillary electrophoresis in a QIAxcel 
Advanced system [QIAGEN]. The pools were diluted to a final concentration of 12 pM and 
loaded for sequencing on the MiSeq platform [Illumina], according to the manufacturer’s 
instructions. 
The trimmed FASTQ files were generated using MiSeq Reporter [Illumina]. Alignment 
and variant calling were performed using NextGENe (v.2.4.2) [SoftGenetics, State College, PA, USA] 
with .vcf files being imported into Geneticist AssistantTM [SoftGenetics] for variant annotation 
and filtering. All variants detected by NGS were confirmed by Sanger sequencing. 
 
III.3 RAD51C germline variant analysis by Sanger sequencing 
 
RAD51C germline variant analysis was performed in 50 DNA samples by Sanger 
sequencing of all entire coding regions (exons 1-9) and flanking splice junctions. For this 
purpose, DNA was amplified in a solution containing 10x Taq reaction buffer [Thermo Fisher 
Scientific, Waltham, Massachusetts, USA] (75mM Tris-HCl, 20 mM (NH4)2SO4), 1.5 mM of MgCl2 [Thermo 
Fisher Scientific],  0.5 mM dNTP mix [Thermo Fisher Scientific], 0.33 mM of each primer (reverse and 
forward) [Frilabo, Portugal], 1 U of Taq DNA polymerase [Thermo Fisher Scientific] and bidestilled sterile 
water [B. Braun, Foster City, CA, USA] in a final reaction volume of 25μL. The sequence of each 
primer used for the amplification of RAD51C exons are represented in table 9. PCR 
reaction was performed in a thermocycler [Perkin-EImer, Gene Amp PCR Systern 9700, Waltham, Massachusetts, 
USA] according to the following conditions: an initial denaturation step at 94ºC for 10 
12 cycles 
33 
 
5 cycles 
5 cycles 
25 cycles 
minutes, followed by 35 cycles of denaturation, annealing and extension step as 
represented in table 10, and a final extension step at a 72ºC for 10 min. 
Table 9 – Primers used for PCR. 
RAD51C 
Primer Nucleotide sequence 
1F 5’-TCC GCT TTA CGT CTG ACG TC-3’ 
1R 5’-AGG CGA GAG AAC GAA GAC TG-3’ 
2F 5’-TCC ACT CCT AGC ATC ACT GTT GT-3’ 
2R 5’-ACC CAC CCT TAA AAG GAG AAC ACT T-3’ 
3F 5’-ACA TTT CTG TTG CCT TGG GGA GT-3’ 
3R 5’-TGC TGA GGT CTC AGA TGG GCA C-3’ 
4F 5’-ACA ATT GCC AAT ACA TCC AAA CAG GT-3’ 
4R 5’-AGA GAT TTT CTC AAT TGG CTT TGA CTT TG-3’ 
5F 5’-AGA AGG TCC CTG CTC TCT TGG A-3’ 
5R 5’-TGT CAG GCA AAC GCT ATT TTG ACA T-3’ 
6F 5’-CAA AGA GAC TCA CCT AAT TTT CTT ACA TTT TGT-3’ 
6R 5’-ACC AGT GAA CAA GAC AAA TAC AGT CTG C-3’ 
7F 5’-TGA TCA GAG GCG TTC TGA GAA ATG T-3’ 
7R 5’- AGT GTC ACT TCA TGG GTC ACT GT-3’ 
8F 5’-ACA TAC GGG TAA TTT GAA GGG TGT ATT T-3’ 
8R 5’-TGC TTG CTG CCT ACA GAA GTT GAC A-3’ 
9F 5’-CAC AGT GGT TGA TAA ATT TCT ATC TCA AG-3’ 
9R 5’-TGG ATT CAT TCA TGC CAT AGT GTG T-3’ 
F: Forward; R: Reverse. 
Table 10 – PCR program used for amplification of all exons of the RAD51C gene. 
Step Temp Time 
Denaturation 94ºC 1 min 
Annealing 58ºC 1 min 
Extension 72ºC 1 min 
 
Step Temp Time 
Denaturation 94ºC 1 min 
Annealing 54ºC 1 min 
Extension 72ºC 1 min 
Step Temp Time 
Denaturation 94ºC 1 min 
Annealing 56ºC 1 min 
Extension 72ºC 1 min 
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 Amplified PCR products were then analyzed by high-resolution capillary 
electrophoresis in a QIAxcel Advanced system [QIAGEN] and the electrophoresis results 
were analyzed using the QIAxcel ScreenGel software [QIAGEN]. 
The ExoSAP-IT method was used to remove excess of primers, enzymes, salts 
and dNTPs from the PCR amplification products. Briefly, to 5 μL of the PCR products 
were added 2 μL of ExoSAP solution (Exonuclease I [Thermo Fisher Scientific] (20 U/μL) and Fast 
Thermosensitive Alkaline Phosphatase [Thermo Fisher Scientific] (1 U/μL), in a proportion of 1:2, 
followed by incubation at 37ºC for 50 minutes, and enzyme inactivation at 85ºC for 15 
minutes. 
The purification was followed by the sequencing reaction using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit [Applied Biosystems]. The reaction consisted on mixing 3.4 
μL of sequencing buffer, 0.5 μL of BigDye® Terminator v3.1 (containing dNTPs, ddNTPs-
fluorocromes, MgCl2 and Tris-HCl buffer), 0.32 μL of one of the corresponding primer 
(forward or reverse), bidestilled sterile water [B. Braun] and 1.0 μL of the purified DNA to 
reach a final reaction volume of 10 μL. The sequencing reaction was performed according 
to the conditions of table 11. 
Table 11 – PCR program of sequencing reaction. 
Step Temp Time  
Initial Denaturation 95ºC 4 min 
Denaturation 95ºC 10 sec 
Annealing 50ºC 10 sec 
Extension 60ºC 2 min 
Final Extension 60ºC 10 min 
 
To remove excess of dNTPs, labelled ddNTPs, and non-incorporated primers, the 
sequencing products were purified with IIlustra Sephadex® G-50 fine [GE Healthcare, Life Sciences, 
Cleveland, USA], according to standard procedures. After purification, 15 μL of Hi-Di
TM 
Formamide [Applied Biosystems] were added to the sequencing products to help stabilize the 
single stranded DNA. The products were then analyzed in a 3500 Genetic Analyzer [Applied 
Biosystems] by capillary electrophoresis. The electropherograms of each sample were 
analyzed with the Sequencing Analysis Software v5.4 [Applied Biosystems]. All of them were 
examined at least twice, reviewed manually and with the Mutation Surveyor® DNA Variant 
Analysis Software v4.0.8 [Softgenetics] by two independent observers.   
35 cycles 
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IV. RESULTS 
IV.1 RAD51C germline variants  
 
IV.1.1 NGS cohort 
 
We analyzed using NGS 61 DNA samples from patients with clinical criteria for 
molecular testing for LFS. Two heterozygous variants were found in the RAD51C gene, 
including the one who triggered this project, corresponding to a frequency of 3.3% of 
RAD51C germline variants (see table 12).   
Table 12 – Germline variants found in the RAD51C gene in the NGS cohort. 
Sample 
number 
cDNA description 
Exon 
number 
Protein description Effect 
Biological 
significance 
#22 c.709C>T 5 p.(Arg237Ter) Nonsense Pathogenic 
#25 c.890_899del 6 p.(Leu297HisfsTer2) Frameshift Pathogenic 
 
IV.1.2 Retrospective cohort 
 
In the retrospective cohort we analyzed 50 DNA samples using Sanger 
sequencing from patients with clinical criteria for molecular testing for LFS. We found a 
heterozygous variant (table 13) in one patient, corresponding to a frequency of 2% of 
RAD51C germline variants. 
Table 13 – Germline variants found in the RAD51C gene in the retrospective cohort. 
Sample 
number 
cDNA description 
Exon 
number 
Protein description Effect 
Biological 
significance 
#6 c.890_899del 6 p.(Leu297HisfsTer2) Frameshift Pathogenic 
  
IV.2 Description of RAD51C variants 
 
The variant found in sample #22 (figure 8) consists of a nonsynonymous 
substitution of a cytosine for a thymine (transversion, c.709C>T) in the first position of 
codon 237 (CGA → TGA) that creates a premature translational stop signal in this codon. 
This alteration is expected to result in an absent or disrupted protein product. This variant 
was reported in the literature in a patient with thyroid and ovarian cancer (Blanco et al., 
2014), in a patient with gastric cancer (Sahasrabudhe et al., 2017), and in a patient with 
family history of breast and/or ovarian cancer (Tavera-Tapia et al., 2017). 
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Figure 8 – Visualization of RAD51C reads using the Integrative Genomics Viewer (IGV) in 
patient #22 
The second variant consists of a deletion of 10 base pairs (TTGTTCCTGC) that 
starts in the nucleotide 890 in exon 6 (see figure 9). This variant leads to an alteration in 
the reading frame and was found in the two cohorts: samples #25 and #6. This genetic 
variation was described in the literature in a patient with colorectal cancer (Yurgelun et al., 
2015) and in a patient with bladder and early-onset prostate cancer (Paulo et al., 2018). 
 
 
  
 
 
 
 
 
 
 
Figure 9 – Variant c.890_899del by NGS and Sanger sequencing: A. Alignment of the RAD51C 
gene by Integrative Genomics Viewer (IGV) obtained by analysis of sample #25; B. Sanger 
sequence electropherogram obtained from sample #6. 
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IV.3 Clinical characteristics of RAD51C variant carriers 
 
Sample #22 is from a family with classic criteria for LFS. The index patient is a 
woman who was diagnosed with a pleomorphic undifferentiated liposarcoma at the age of 
59. We were able to perform, after genetic counselling, screening of the pathogenic 
RAD51C variant in 11 family members. Seven relatives are carriers of the variant, 
including a sister with a gastrointestinal stromal tumor, a type of sarcoma (figure 10). 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Pedigree of patient #22, indicating the relatives that were tested for the RAD51C 
variant (+ for carriers and - for non-carriers). 
 
The patient corresponding to sample #25 is a man who was diagnosed with a 
spindle cell liposarcoma on the anterolateral region of the left thigh at 50 years old. The 
pedigree is shown in figure 11.  
 
 
 
 
 
 
 
Figure 11 – Pedigree of patient #25. 
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 Patient #6 was diagnosed with a gastric carcinoma at 39 years of age. Two years 
later he was diagnosed with a lymphoma and, six years later, with a low grade 
leiomyosarcoma in the fourth finger of the left hand (figure 12). His 38 years old son was 
also shown to be a carrier. 
 
 
 
 
 
 
 
 
Figure 12 – Pedigree of patient #6.  
 
IV.4 Other germline variants in the NGS cohort 
 
 In the 61 samples analyzed by NGS, we identified four potentially deleterious 
germline variants in other genes (table 14).  
Table 14 – Other germline variants found in the NGS cohort. 
Sample 
number 
Mutated 
gene 
cDNA 
description 
Exon 
number 
Protein 
description 
Effect 
Biological 
significance 
#19 FANCA c.295C>T 4 p.(Gln99Ter) Nonsense 
Pathogenic in 
homozygosity 
#40 CHEK2 c.1169A>C 12 p.(Tyr390Ser) Missense Likely pathogenic 
#57 BUB1B c.709_712del 6 p.(Thr237GlnfsTer8) Frameshift Not described 
#61 FANCM c.1972C>T 11 p.(Arg658Ter) Nonsense VUS 
VUS: Variants of uncertain significance. 
 
 Patient #19 presents a germline variant that consists of a substitution of a cytosine 
for a thymine (transversion, c.295C>T) in nucleotide 295 of the FANCA gene, leading to a 
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premature translational stop signal in codon 99. In the literature, this variant was classified 
as pathogenic in homozygosity causing Fanconi Anemia (Callen et al., 2005).  
Patient #40 presents a missense variant in CHEK2 that substitutes an adenine for 
a cytosine in nucleotide 1169. This variant was described in a series of non-BRCA breast/ 
ovarian cancer families and was showed to have a deleterious effect in the CHK2 protein 
(Desrichard et al., 2011). 
 Patient #57 presented a four base pair deletion (ACAG) that starts in nucleotide 
709 of BUB1B exon 6. This variant results in a modification in the reading frame and has 
not been previously described. 
The alteration found in sample #61 was a germline variant that consists in a 
substitution of a cytosine for a thymine (transversion, c.1972C>T) on the FANCM gene, 
leading to the formation of a premature translational stop signal in codon 658. This variant 
was found in several studies in non-BRCA breast/ ovarian cancer families, but the 
significance of this alteration remains uncertain (Renwick et al., 2006; Nguyen-Dumont et 
al., 2018; Silvestri et al., 2018). 
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V. DISCUSSION 
 
Since the initial report in 1969 describing LFS as an inherited disease with high 
predisposition to develop rhabdomyosarcomas, breast cancer and several other cancers, 
many authors have been studying this syndrome in order to better understand its 
molecular basis and to implement appropriate surveillance programs to improve the 
overall survival of the affected families. After more than four decades of research to 
identify the gene or genes associated with this syndrome, TP53 is still the only gene 
consistently associated with the predisposition to develop the heterogeneous spectrum of 
malignancies typical of LFS. Although many pathogenic germline variants have already 
been described in TP53, there are still several families that comply with the LFS genetic 
testing criteria who do not have variants in this gene. Only about 20-40% of the families 
with the Chompret criteria and 70% of those with the classic LFS criteria present a 
pathogenic TP53 variant, therefore further studies are required to explain cancer 
predisposition in the remaining families (Gonzalez et al., 2009b; Tinat et al., 2009). 
The present study includes 111 families that were tested in the Genetics 
Department of IPO-Porto and were negative for non-benign TP53 variants. These families 
were in this study tested for RAD51C variants by different methodologies and we found 
three families with a RAD51C pathogenic germline variant: one family with variant 
c.709C>T, p.(Arg237Ter), and two families with variant c.890_899del, 
p.(Leu297HisfsTer2), corresponding to a prevalence of 2.7% (3/111). Considering all 
families with Chompret or classic criteria studied in the Genetics Department of IPO-Porto 
between 2000-2016 (n=127), the prevalence of RAD51C pathogenic variants was 2.4% 
(3/127) and the prevalence of TP53 pathogenic variants was 12.6% (16/127) (data not 
shown). If we consider all families identified with a pathogenic variant either in the TP53 
gene or in RAD51C gene, we observe that the contribution of RAD51C pathogenic 
variants is about 15.8% (3/19). 
The variant RAD51C c.709C>T was identified by NGS in a family with classic 
criteria for LFS. The initial index patient was diagnosed with a soft tissue sarcoma at the 
age of 59. Although the origin of the variant (maternal or parental side) is still not known, it 
should be noted that the paternal side of the family presents several individuals affected 
with different types of cancer belonging to the LFS tumor spectrum, namely, soft tissue 
sarcoma, lung cancer, brain cancer, and leukemia. We were able to study 11 relatives, of 
which seven are carriers of the variant identified in the index patient. Of all carriers, two 
developed soft tissue sarcomas, one had an adrenal adenoma, another had multiple 
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thyroid nodules and the remaining carriers are under 44 years old and healthy. This 
variant is classified in the ClinVar Database as pathogenic, as the substitution of a 
cytosine for a thymine creates a premature translational stop signal in the exon five. This 
variant has been reported in the literature in three individuals, one with hereditary diffuse 
gastric cancer, one with thyroid and ovarian cancer, and another with family history of 
breast and/or ovarian cancer (Blanco et al., 2014; Sahasrabudhe et al., 2017; Tavera-
Tapia et al., 2017). The tumor from one of these patients reported in the literature 
presented an enriched mutation signature indicative of HR defects, reinforcing the 
evidence for the causality and pathogenicity of this mutation (Sahasrabudhe et al., 2017).  
The RAD51C c.890_899del variant was identified in two index cases, one detected 
by NGS and the other by Sanger sequencing in the retrospective series, and no evidence 
was found of the two families being related. The first patient is a man diagnosed with a 
soft tissue sarcoma and with both parents affected with different cancers, the mother with 
gastric cancer at 42 years old and the father with colon cancer at 72 years old. 
Unfortunately, it was not possible to determine the origin of the variant (maternal or 
paternal) or if it arose de novo. The second patient presents multiple tumors: gastric 
cancer diagnosed at 39 years of age, lymphoma diagnosed at 41 years of age and a soft 
tissue sarcoma diagnosed at 47 years of age. This patient had six siblings, of which one 
sister was affected with ovarian cancer at 68 years of age and another sister with colon 
cancer at 62 years old, but it was not possible to carry out segregation studies in this 
family. This variant leads to an alteration of the reading frame causing a premature 
translational stop signal, which results in the loss of 80 amino acids at the protein C-
terminus, including the nuclear localization motif, being therefore classified in ClinVar 
Database as pathogenic. In the literature, this variant was described in a patient with 
colon cancer (Yurgelun et al., 2015) and in an individual with bladder cancer and early-
onset prostate cancer (Paulo et al., 2018). In our work, the identification of this variant in 
two families was only possible due to the incorporation of gastric cancer in the tumor 
spectrum of LFS to comply with the Chompret criteria. These results reinforce the 
importance of including gastric cancer in the LFS tumor spectrum in countries with high 
incidence for gastric carcinoma, as is the case of Portugal, as we have previously shown 
regarding the identification of TP53 variants (Keller et al., 2004; Kim et al., 2004; Pinto et 
al., 2009).  
Germline variants in the RAD51C gene have been identified in patients with breast 
and ovarian cancer without BRCA mutations, although more predominantly in families with 
history of ovarian cancer, so RAD51C is primarily considered an ovarian cancer 
susceptibility gene (Sopik et al., 2015). However, RAD51C pathogenic variants have been 
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reported in patients with other types of neoplasias, such as lung, kidney, colorectal, 
pancreatic, thyroid, prostate, gastric, head and neck cancer, as well as with leukemia and 
lymphoma (Meindl et al., 2010; Vuorela et al., 2011; Blanco et al., 2014; Scheckenbach et 
al., 2014; Yurgelun et al., 2015; Sahasrabudhe et al., 2017; Paulo et al., 2018). Our study 
is the first to identify RAD51C pathogenic germline variants in families with classic LFS 
criteria and in patients with the Chompret criteria for TP53 mutation testing. The fact that 
we found RAD51C variants in four patients with soft tissue sarcomas in three different 
families, one of them with classic LFS criteria, is a strong argument for its role as an 
alternative cause of LFS besides TP53. However, given the phenotypic diversity of LFS, 
we cannot exclude the possibility that RAD51C mutations increase the risk for several 
different cancers, with some families complying with the clinical criteria for LFS by chance. 
The identification of TP53 pathogenic germline variants in LFS families allows predictive 
tests and specific surveillance programs to variant carriers. According to the NCCN 
Guidelines, pathogenic germline variants in the RAD51C gene should be offered risk-
reducing salpingo-oophorectomy due to the high risk of development of ovarian cancer. 
More studies are needed to determine the risk for other cancers in RAD51C variant 
carriers to allow development of specific surveillance programs, but for now surveillance 
programs for other cancers must be based on family history.  
Recent reports have proved the efficacy of PARP inhibitors as targeted therapy for 
patients with deficient HR. PARP enzymes are key components in the activation and 
recruitment of repair enzymes at sites of a single strand breaks (SSBs)(Fong et al., 2009). 
PARP inhibitors block these enzymes and lead to the accumulation of this type of errors, 
which will lead to the collapse of DNA replication forks and formation and accumulation of 
DSBs (Walsh, 2015). In cancers with deficient HR, DSBs will not be repaired and cause 
cell death, a concept known as synthetic lethality (Farmer et al., 2005). The Food and 
Drugs Administration (FDA) have already approved the use of PARP inhibitors for the 
treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer in adult 
patients with deleterious BRCA variants and in BRCA-mutated metastatic breast cancer, 
and several clinical trials are ongoing in other cancers. Some studies have shown that 
tumors deficient in other genes involved in HR may respond also to these inhibitors 
(McCabe et al., 2006). Since RAD51C is involved in HR, it is likely that in the future LFS 
patients with pathogenic variants in this gene might be eligible for this targeted therapy. 
In our cohort, we also found potentially deleterious germline variants in the genes 
BUB1B, CHEK2, FANCA and FANCM in four patients. The BUB1B gene encodes a 
protein called BUBR1, a multidomain protein kinase that has an important role in the 
mitotic spindle assembly checkpoint (SAC) (Kapanidou et al., 2015). This checkpoint 
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certifies the correct chromosome segregation during anaphase, ensuring that each sister 
chromatid is attached to a spindle microtubule. Biallelic pathogenic variants in BUB1B 
were identified in families with mosaic variegated aneuploidy (MVA), an autosomal 
recessive disorder characterized by mosaic aneuploidies involving multiple chromosomes 
(Hanks et al., 2004; Matsuura et al., 2006). Individuals affected with MVA present growth 
retardation, profound developmental delay, severe microcephaly, and other disabilities, 
having also a high risk of developing some specific neoplasms such as 
rhabdomyosarcoma, Wilms tumor and leukemia (Kajii et al., 2001). Homozygous variants 
in the BUB1B gene were also identified in a patient with gastrointestinal early-onset 
cancer (Rio Frio et al., 2010). The truncated BUB1B variant described in patient #57 has 
so far not been described in the literature and was found in heterozygosity. The 
significance of this alteration and its association to cancer susceptibility remains to be 
clarified. 
The CHEK2 gene encodes the CHK2 protein that, once activated, inhibits the 
CDKs and consequently blocks the progression of the cell cycle for mitosis after DNA 
damage. The identification of germline heterozygous mutations in the CHEK2 gene in 
some families with clinical criteria for LFS suggested that this gene would be a possible 
candidate for the cause of the LFS phenotype (Bell et al., 1999; Vahteristo et al., 2001). 
Although this hypothesis was not supported by other studies, CHEK2 remains as a breast 
cancer susceptibility gene, the most common cancer in the adult phase in TP53 carriers 
(Amadou et al., 2018). For some specific pathogenic variants in CHEK2, the cumulative 
risk for breast cancer in women with familial breast cancer was estimated to be around 28 
to 37% (Weischer et al., 2008; Cybulski et al., 2011). Some variants were also associated 
with high risk for prostate cancer (Walsh et al., 2006; Wang et al., 2015) and some 
heterozygous germline variants were found in patients with pancreatic and colorectal 
cancers (Yurgelun et al., 2017; Chaffee et al., 2018; Stoffel et al., 2018). The missense 
variant detected in our work is classified as likely pathogenic in the ClinVar Database, 
detected in a patient diagnosed with a breast cancer at 36 years old with two relatives 
diagnosed with leukemia at young ages. Segregation studies will be required to better 
evaluate the pathogenicity of this variant and its correlation with the phenotype presented 
by the family. 
FANCA and FANCM are involved in the FA pathway and biallelic alterations in 
these genes are known to lead to FA and consequently susceptibility to cancer (Nalepa 
and Clapp, 2018). However, heterozygous variants in other FA genes within the HR 
pathway are known to cause predisposition to breast and/or ovarian cancer, namely, 
BRCA1, BRCA2, BRIP1, PALB2, and RAD51C (Wooster et al., 1995; Bonadona et al., 
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2005; Levran et al., 2005; Xia et al., 2006; Meindl et al., 2010). Using the International 
Fanconi Anemia Registration (IFAR) data, Berwick and co-workers analyzed 312 families 
of probands diagnosed with FA and identified more than 404 heterozygous FA carriers in 
the most known genes involved in the FA pathway (FANCA/B/C/D1/D2/E/F/G/J). 
According to their results in general, excluding variants in FANCD1/BRCA2, there is not a 
striking or significant increase in cancer incidence among the FA heterozygotes, with only 
some evidence that FANCC variants may slightly increase the susceptibility to breast 
cancer (Berwick et al., 2007). However, more recently some studies have made 
associations between heterozygous variants in these FA genes and an increased risk to 
develop cancer. Solyom and co-workers, identified a heterozygous deletion in the FANCA 
gene that predispose to breast cancer, and Kiiski and colleagues identified FANCM 
variants in patients with triple-negative breast cancers and proposed this gene as a breast 
cancer susceptibility gene (Solyom et al., 2011; Kiiski et al., 2014). The identification in the 
present work of two truncating variants in these two genes (FANCA and FANCM) in 
patients with clinical criteria for LFS reinforces the hypothesis that heterozygous 
alterations in these FA genes might be involved in predisposition to cancer. However, 
more studies are needed to clarify the effect of these alterations in cancer predisposition 
and, consequently, to better understand their clinical significance and their potential role in 
LFS.  
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VI. CONCLUSIONS 
This study allows us to conclude that: 
 Pathogenic germline variants in RAD51C are present in about 2.7% of 
families with clinical criteria for LFS molecular testing that were negative for non-benign 
TP53 variants; 
 Although RAD51C variants are mainly known to be associated with 
increased risk for ovarian cancer, this study found that families carrying them have 
frequently soft tissue sarcomas and gastric cancers; 
 The identification of pathogenic germline variants in LFS families allows 
carriers to be referred to surveillance programs, potentially improving prognosis and 
increasing the overall survival, but further studies are required to define the risk of cancer 
associated with RAD51C pathogenic variants; 
 Other genes involved in the FA pathway and/or cell cycle regulation might 
play a role in families with a tumor spectrum associated with LFS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
54 
 
  
   
 
 
VII. FUTURE 
PERSPEC
TIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
VII.   FUTURE PERSPECTIVES 
  
56 
 
 
  
57 
 
VII. FUTURE PERSPECTIVES 
 This study may benefit from further analysis to support our conclusions and to 
allow a more specific evaluation of the RAD51C germline variant carriers and the 
association with the phenotype of LFS. Thus, we plan:  
 
 To find out if there is loss of heterozygosity in the tumors of germline variant 
carriers; 
 To complete the segregation analysis in the families identified, including the study 
of archival tissue of deceased relatives, in order to better understand the 
correlation between these variants and the phenotype;  
 To perform haplotype studies in the two families sharing the c.890_899del variant 
to find out if they are related and thereby extend the co-segregation data. If 
possible, the haplotype study might be extended to other cancer families carriers 
of the two RAD51C variants here reported in LFS-like families; 
 Look for exonic rearrangements in RAD51C using the available NGS data and 
MLPA. 
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